At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHVS Pharvaris N.V.
Trading 05-14 14:54:27 EDT
20.90
-0.27
-1.27%
High21.50
Low20.87
Vol15.23K
Open21.50
D1 Closing21.17
Amplitude2.98%
Mkt Cap1.12B
Tradable Cap460.29M
Total Shares53.82M
T/O323.22K
T/O Rate0.07%
Tradable Shares22.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Pharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy Rating
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.